ProCE Banner Activity

Assessing Adverse Events in Patients Receiving Chemoimmunotherapy Regimens for Non-Small-Cell Lung Cancer

Tool

Use this Interactive Decision Support Tool to aid in the evaluation of adverse events in patients receiving combination chemoimmunotherapy regimens for non-small-cell lung cancer.

Released: October 19, 2023

Share

Faculty

Marianne Davies

Marianne Davies, DNP, ACNP, FAAN

Associate Professor
Yale School of Nursing
Senior Advanced Practice Nurse
Smilow Cancer Hospital at
Yale New Haven
Yale Comprehensive Cancer Center
New Haven, Connecticut

Matthew Gubens

Matthew Gubens, MD, MS

Professor of Medicine
Medical Director
Thoracic Medical Oncology
University of California
San Francisco, California 

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Faculty Disclosure

Primary Author

Marianne Davies, DNP, ACNP, FAAN

Associate Professor
Yale School of Nursing
Senior Advanced Practice Nurse
Smilow Cancer Hospital at
Yale New Haven
Yale Comprehensive Cancer Center
New Haven, Connecticut

Marianne Davies, DNP, ACNP, FAAN, has no relevant financial relationships to disclose.

Matthew Gubens, MD, MS

Professor of Medicine
Medical Director
Thoracic Medical Oncology
University of California
San Francisco, California 

Matthew Gubens, MD, MS: consultant/advisor/speaker: AnHeart, AstraZeneca, Atreca, Cardinal Health, Genentech/Roche, Genzyme, Gilead, Guardant, Invitae, iTeos, Merus, Sanofi, Summit, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.